台北全球共识II:幽门螺杆菌筛查与根除预防胃癌
该共识由12国32名专家采用GRADE框架和Delphi法制定,达成28条共识。共识认为根除幽门螺杆菌可降低各年龄段胃癌风险,癌前病变前根除获益最大,推荐对高风险人群筛查,并建议所有感染的成人接受根除治疗。
要点
- 根除幽门螺杆菌可降低各年龄段胃癌风险,癌前病变发生前根除获益最大。
- 筛查应优先高风险人群,首选13C尿素呼气试验或单克隆粪便抗原检测。
- 高抗生素耐药地区推荐铋剂四联经验性根除,并强烈建议根除后确认检测。
核心结论
- 根除幽门螺杆菌是有效的胃癌预防策略,应提供给所有感染的成人个体。
研究设计与样本
- 来自12个国家的32名专家采用GRADE框架评估证据,并用Delphi法达成≥80%共识,共形成28条共识声明。
主要发现
- 根除幽门螺杆菌可降低所有年龄组的胃癌风险,癌前病变发生前根除风险降低幅度最大。
- 根除幽门螺杆菌可促进溃疡愈合、预防溃疡复发并降低NSAID/阿司匹林相关溃疡风险。
- 幽门螺杆菌传播主要在家庭内发生,以家庭为基础的方法有望减少传播并改善治疗结局。
- 幽门螺杆菌根除不增加反流性食管腺癌风险。
关键数值与推荐
- 筛查应优先高风险人群,首选13C尿素呼气试验或单克隆粪便抗原检测。
- 在低患病率地区,经验证血清学检测可作为可行替代方案,但后续需非血清学确认检测。
- 高幽门螺杆菌抗生素耐药地区推荐经验性根除治疗,尤其是铋剂四联疗法;钾离子竞争性酸阻滞剂方案为替代选择。
- 强烈建议进行确认检测以确保幽门螺杆菌根除。
- 对于胃癌高风险和/或报警症状的幽门螺杆菌感染者,建议行内镜检查。
临床怎么用
- 将幽门螺杆菌筛查整合到现有健康计划中,可能优化患者依从性和资源利用。
- 对感染的成人个体应提供根除治疗,高风险人群优先筛查。
- 根除治疗后应进行确认检测以验证根除成功。
局限性
- 长期菌群和耐药组扰动以及抗生素使用增加的环境影响需进一步研究。
- 幽门螺杆菌疫苗的研发仍是未满足的需求。
- 基于先进遗传研究的风险分层方法尚待建立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To convene a global consensus on Helicobacter pylori (H pylori) screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions. METHODS: 32 experts from 12 countries developed and refined consensus statements on H pylori management, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess evidence and the Delphi method to achieve ≥80% agreement. RESULTS: Consensus was achieved on 28 statements. Eradication of H pylori, the primary cause of gastric cancer, reduces the risk of gastric cancer across all age groups, with the greatest risk reduction before the onset of premalignant conditions. H pylori eradication also promotes ulcer healing, prevents ulcer recurrence and reduces the risk of NSAID/aspirin related ulcers. H pylori transmission primarily occurs within families, making family based approaches promising for reducing spread and improving treatment outcomes. H pylori screening should prioritise high risk populations. 13C-urea breath test or monoclonal stool antigen tests are preferred. Validated serological testing is a feasible alternative in low prevalence settings when followed by confirmatory non-serological testing. Integrating H pylori screening into existing health programmes may optimise patient adherence and resource utilisation. Empiric eradication treatment, especially bismuth quadruple therapy, is recommended in regions with high H pylori antibiotic resistance for conventional antibiotics. Potassium competitive acid blocker based regimens are alternatives. Confirmatory testing is strongly recommended to ensure H pylori eradication. Endoscopy is suggested for H pylori infected individuals with a high risk of gastric cancer and/or alarm features. H pylori eradication does not increase the risk of reflux oesophageal adenocarcinoma. Long term disruptions to the microbiota and resistome, as well as the environmental impact of increased antibiotic use, warrant further investigation. The development of an H pylori vaccine remains an unmet need, as does the establishment of a risk stratified approach informed by advanced genetic research. CONCLUSION: H pylori eradication is an effective prevention strategy for gastric cancer that should be offered to all infected adult individuals. Future research should prioritise determining the optimal timing for screening, evaluating long term individual and population outcomes, as well as identifying more precise risk stratification parameters.
引用
- Liou JM, Malfertheiner P, Hong TC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II. Gut. 2025. PMID: 40912906. doi:10.1136/gutjnl-2025-336027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。